Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia

NEXT STORY
GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates
PREV STORY
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Photopheresis Products Market (2021 to 2029) – Featuring Terumo, Med Tech Solutions and PIT Medical Systems Among Others

author_avatar
NASDAQ Market News

CB2 Insights Completes Acquisition of Cannabis Evaluation Clinics in Arizona and Colorado

author_avatar
NASDAQ Market News

Altimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update

author_avatar
NASDAQ Market News